#1 Clinical Trials Search in Europe

Resatorvid

Resatorvid, also known as TAK-242, is a drug being studied in clinical trials for its potential to treat severe sepsis. This condition is a serious medical problem characterized by the body’s extreme response to infection, leading to organ dysfunction and potentially death. The drug works by suppressing the release of inflammatory substances in the body, offering hope for improved outcomes in patients with this life-threatening condition.

Table of Contents

What is Resatorvid?

Resatorvid, also known by its research name TAK-242, is a medication being developed to treat a serious medical condition called severe sepsis[1]. It’s important to note that Resatorvid is still in the experimental stage and is not yet approved for general use. Researchers are studying this drug to see if it can help patients with severe infections that affect their whole body.

How Resatorvid Works

Resatorvid is designed to work in a specific way in the body. It’s called a toll-like receptor 4 inhibitor[2]. To understand this, let’s break it down:

  • Toll-like receptors: These are like security guards on the surface of certain cells in your body. They help recognize when harmful bacteria or other threats are present.
  • Cytokines: When the toll-like receptors detect a threat, they signal the body to produce substances called cytokines. Cytokines help fight infections, but too many can cause harm.
  • Resatorvid’s role: This drug aims to block one specific type of toll-like receptor (number 4). By doing this, it may help reduce the overproduction of cytokines that can occur in severe sepsis.

The goal of Resatorvid is to suppress the release of inflammatory cytokines, which are believed to contribute to the severe symptoms seen in sepsis[1].

Target Condition: Severe Sepsis

Severe sepsis is a very serious medical condition that occurs when the body’s response to an infection goes into overdrive. Here’s what you need to know about it:

  • It’s defined as sepsis associated with acute organ dysfunction[1].
  • In the United States, about 750,000 cases of severe sepsis occur each year[1].
  • The mortality rate (chance of dying) for severe sepsis patients with organ dysfunction ranges between 30% and 50%[1].
  • As the population ages, these numbers are expected to increase[1].

Severe sepsis can lead to widespread damage in blood vessels, multiple organ failure, and potentially death if not treated promptly and effectively[1].

Clinical Trials of Resatorvid

Researchers have conducted clinical trials to study the effectiveness and safety of Resatorvid in treating severe sepsis. These trials are carefully designed studies that help determine if a new treatment works and is safe. Here are some key points about the Resatorvid trials:

  • The studies were randomized, double-blind, and placebo-controlled. This means that participants were randomly assigned to receive either Resatorvid or a placebo (a substance that looks like the drug but has no active ingredients), and neither the patients nor the doctors knew who was getting which treatment[1][2].
  • Different doses of Resatorvid were tested to find the optimal amount for treatment[1].
  • One study focused on patients with severe sepsis[1], while another looked specifically at patients with sepsis-induced cardiovascular and respiratory failure[2].
  • The studies were conducted in multiple centers across different countries, involving adult patients[1][2].

It’s important to note that one of the studies was ended early after an analysis showed insufficient cytokine suppression in the initial group of subjects[1]. This highlights the challenges in developing new treatments for complex conditions like severe sepsis.

How Resatorvid is Administered

In the clinical trials, Resatorvid was given to patients in the following ways:

  • It was administered as an injection under the skin (subcutaneously) or as an intravenous infusion (directly into a vein)[1][2].
  • The treatment typically started with an initial dose given over 30 minutes, followed by a continuous infusion over 96 hours (4 days)[1][2].
  • Different dosages were tested, including 1.2 mg/kg/day and 2.4 mg/kg/day[1][2].

The exact method of administration may change if Resatorvid is approved for use in the future, based on the results of these and other studies.

Outcomes Measured in Resatorvid Studies

To determine if Resatorvid is effective and safe, researchers looked at several important outcomes in the clinical trials. These included:

  1. 28-day All-cause Mortality: This measures how many patients survived for 28 days after starting treatment, regardless of the cause of death[1][2].
  2. Organ Failure Assessment: This looks at how well the patients’ organs were functioning before and after treatment[1].
  3. Systemic Inflammatory Response: This measures the level of inflammation in the body[1].
  4. Vasopressor-free days: This counts the number of days patients didn’t need medications to support their blood pressure[1][2].
  5. Ventilator-free days: This measures how many days patients could breathe on their own without mechanical help[1][2].
  6. Intensive Care Unit (ICU) free days: This counts how many days patients were well enough to be out of the ICU[1][2].

These outcomes help researchers understand if Resatorvid is making a meaningful difference in the health and recovery of patients with severe sepsis.

Aspect Details
Drug Name Resatorvid (TAK-242)
Condition Studied Severe Sepsis
Mechanism of Action Inhibits TLR-4 mediated signaling, suppressing cytokine release
Administration Subcutaneous or intravenous injection
Dosage 1.2 mg/kg/day or 2.4 mg/kg/day
Duration of Treatment 96 hours (4 days)
Primary Outcome 28-day all-cause mortality
Secondary Outcomes Organ function, ICU-free days, vasopressor-free days, ventilator-free days
Study Design Randomized, double-blind, placebo-controlled

FAQ

  • What is Resatorvid? Resatorvid, also known as TAK-242, is a small molecule drug that suppresses the release of inflammatory substances in the body. It works by inhibiting a specific receptor called TLR-4, which is involved in the body's immune response to infections.
  • What condition is Resatorvid being studied for? Resatorvid is being studied as a potential treatment for severe sepsis, a serious medical condition where the body's response to infection leads to organ dysfunction and can be life-threatening.
  • How is Resatorvid administered in these clinical trials? In the clinical trials, Resatorvid is administered through injection. It is given subcutaneously (under the skin) or as an intravenous infusion, with an initial dose followed by a continuous infusion over 96 hours.
  • What are the main outcomes being measured in these trials? The main outcomes being measured include 28-day all-cause mortality (death from any cause within 28 days), changes in organ function, days free from intensive care unit, ventilator use, and vasopressor medication use.
  • Are there any side effects of Resatorvid mentioned in these trials? The clinical trials information provided does not specifically mention side effects of Resatorvid. However, as with all investigational drugs, researchers are monitoring for safety and efficacy throughout the studies.

Ongoing Clinical Trials on Resatorvid

  • Study on the Safety and Effects of Resatorvid and Filgrastim for Patients with Severe Alcoholic Hepatitis and Acute-on-Chronic Liver Failure

    Not yet recruiting

    1 1
    Investigated diseases:
    Investigated drugs:
    Germany Portugal Spain

Glossary

  • Sepsis: A serious medical condition caused by the body's extreme response to an infection, which can lead to tissue damage, organ failure, and death if not treated promptly.
  • Severe Sepsis: Sepsis associated with acute organ dysfunction, indicating a more serious stage of the condition.
  • Resatorvid: An investigational drug (also known as TAK-242) being studied for the treatment of severe sepsis. It works by suppressing the release of inflammatory substances in the body.
  • Cytokines: Small proteins released by cells that have a specific effect on the interactions and communications between cells, particularly in immune responses.
  • Toll-like Receptor 4 (TLR-4): A type of protein found on the surface of some cells that plays a key role in the body's immune response to infection.
  • Vasopressor: A type of medication that constricts (narrows) blood vessels and is used to treat low blood pressure, particularly in septic shock.
  • Ventilator: A machine that helps a patient breathe by moving air into and out of the lungs.
  • Intensive Care Unit (ICU): A specialized hospital unit that provides intensive care and monitoring for critically ill patients.
  • All-cause Mortality: The death rate from any cause in a group of people over a specific period, often used as a measure of overall risk.
  • Placebo: An inactive substance or treatment used in clinical trials as a control to compare with the effects of the drug being tested.

References

  1. https://clinicaltrials.gov/study/NCT00143611
  2. https://clinicaltrials.gov/study/NCT00633477